Protocol Ledger

NCT04167345 · Phase II · TERMINATED

Evaluation of the Efficacy and Safety of VX-814 in Subjects With the PiZZ Genotype

Interventional Phase II clinical trial protocol NCT04167345 sponsored by Vertex Pharmaceuticals in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-01-13 Enrollment: 48 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04167345
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)48 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04167345
Protocol FieldVerified Registry Value
NCT IdentifierNCT04167345
Consolidated Lead SponsorVertex Pharmaceuticals
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment48 participants (ACTUAL)
Registered Start Date2020-01-13
WhyStopped ClassificationUnspecified

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Vertex Pharmaceuticals across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI